ANALYSIS OF BRCA1 EXPRESSION IN BREAST CANCER BY IMMUNOHISTOCHEMISTRY

RAMOS, J.E.P. (Pontifícia Universidade Católica de Goias), PAES, J.F. (Programa de Pós Graduação em Ciências da Saúde UFG), VILANOVA-COSTA, C.A.S.T. (Laboratório de Biologia Tumoral, ACCG), BASTOS, D.R. (Pontifícia Universidade Católica de Goias), MOTA, E

Pontifícia Universidade Católica de GoiasTo evaluate the expression of BRCA1 protein in breast cancer samples, using immunohistochemistry, and its possible association with the prognosis of the tumors. A group containing 92 paraffin-embedded breast cancer samples was analyzed, including 36 triple-negative (TN) and 56 non-triple-negative (NTN) tumors. BRCA1 expression was evaluated by using anti-BRCA1 monoclonal antibody (MS110, ab16780, ABCAM), and a polymer-associated immunoperoxidase reagent kit (Reveal, DAB, Spring). BRCA1 expression was negative in 58.7% of the tumors and significantly associated with TN phenotype (p=0.035). Patients with TN phenotype presented with lower survival rates than NTN patients (p = 0.044). Five-year survival was higher (78.9%) for BRCA1 positive patients compared to BRCA1 negative patients (57.6%) (p=0.039). The results of this study demonstrated that BRCA1 could be useful in the prognostic evaluation of breast cancer patients. In this study, the absence of BRCA1 expression was associated with a worse survival.BRCA1, breast cancer, Non-triple-negative, Triple-negative.

Return